About Strides Pharma Science Limited

Strides Pharma Science Limited is an Indian pharmaceutical company engaged in the development and manufacture of pharmaceutical products with a corporate office in Bengaluru and registered office at Cyber One, Unit No. 902, Vashi, Navi Mumbai as of February 1, 2025. The equity shares are listed on NSE and BSE, and the Group operates across developed and emerging markets through subsidiaries in India and overseas. As of March 31, 2025, the Group comprised 32 subsidiaries, 1 joint venture, and 3 associates, with 3 subsidiaries in India and 29 overseas; total related entities (including JV and associates) were 36. Key milestones in FY25 included completion of a demerger that led to OneSource Specialty Pharma Limited and its subsidiaries ceasing to be part of the Group, acquisition of the remaining 30% in the Swiss subsidiary now renamed Strides Pharma International AG, formation of a new subsidiary in New Zealand, and consolidation of the consumer healthcare structure under the UK holding company with India and USA subsidiaries. The authorised share capital was increased consequent to the amalgamation of Strides Alathur Private Limited into the Company effective September 12, 2024, and issued, subscribed and paid-up equity stood at 92,162,714 shares as of March 31, 2025.

Strides Pharma Science Limited Business Segment

• The Company reports consolidated revenue from operations of Rs 4,565.33 crore for FY25 from continuing operations; detailed percentage contribution by therapeutic or business vertical and domestic vs. international split is not disclosed in the cited sections and hence is not presented here in line with instructions.
  

Strides Pharma Science Limited Key Management

• Arun Kumar — Non-Executive Director, Chairperson of the Board.

• Badree Komandur — Managing Director & Group CEO.

• G Prakash — Partner, Statutory Auditors’ signing partner (B S R & Co. LLP) referenced in reports; not Company management but included in statutory signatories context within the report.

• Vikesh Kumar — Group CFO.

• Manjula R. — Company Secretary.

Latest Updates on Strides Pharma Science Limited

• Final dividend of Rs 4 per equity share recommended for FY25, subject to shareholder approval, with payment timelines and electronic mode compliance noted per SEBI circulars.

• Registered office shifted to Cyber One, Unit No. 902, Plot No. 4–6, Sector 30A, Vashi, Navi Mumbai 400 703, effective February 1, 2025.

• Risk Management Committee renamed as Risk Management & Sustainability Committee effective May 22, 2025, reflecting integrated oversight of ESG-related risks.

• Appointment of Rao, Murthy & Associates as Cost Auditors for FY26, subject to shareholder ratification; remuneration capped at Rs 4.50 lakh plus taxes and expenses.

• Proposal to appoint V. Sreedharan & Associates as Secretarial Auditors for FY26–FY30, subject to shareholder approval, replacing the long-standing firm after 10+ years.

• Acquisition and corporate actions: completed acquisition of remaining 30% in the Swiss subsidiary (now Strides Pharma International AG) in October 2024; consolidation of Strides Global Consumer Healthcare Limited (UK) to 100% leading to Consumer India and Consumer USA forming part of the Group from August 5, 2024; incorporation of Strides Pharma New Zealand Pty Limited on July 26, 2024; incorporation of Amexel Pte. Ltd. on March 19, 2025.

• Scheme of Arrangement executed: OneSource Specialty Pharma Limited and certain subsidiaries ceased to be part of the Group on November 27, 2024; Strides Alathur Private Limited amalgamated with the Company effective September 12, 2024.

• FY25 sustainability highlight: Debut Sustainability Report for FY24 and an S&P Global CSA score of 76/100 with Top 10 global ranking; featured in the Global Sustainability Yearbook 2025.